Copyright
©The Author(s) 2004.
World J Gastroenterol. Jul 1, 2004; 10(13): 1872-1875
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1872
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1872
Figure 1 The result of enzyme digested pGEX4T-1/hscFv25-mTNFα.
Lane1: mTNFα; Lane 2: hscFv25; Line 3: hscFv25-mTNFα; Lane 4: DNA ladder (100, 250, 500, 750, 1000, 2000 bp).
Figure 2 GST-hscFv25-mTNFα and hscFv25-mTNFα SDS-PAGE Lane 1: Low molecular mass marker (20.
1, 31.0, 43.0, 66.2, 97.4 KD); Lane 2: Preliminarily purified GST-hscFv25-mTNFα; Lane 3: Purified hscFv25-mTNFα.
Figure 3 The remnant tumor tissues treated by hscFv25-mTNFα were positive for TNFα.
The positive granules mainly existed in the cytoplasm of tumor cells. EnVisionTM× 200.
- Citation: Zhang J, Liu YF, Yang SJ, Qiao Q, Cheng H, Zhang CS, Ma FC, Guo HZ. Primary targeting of recombinant Fv-immunotoxin hscFv25-mTNFα against hepatocellular carcinoma. World J Gastroenterol 2004; 10(13): 1872-1875
- URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1872.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1872